Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

63.59 -0.42 (-0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,277,706
Open 64.48
Bid (Size) 63.55 (10)
Ask (Size) 64.00 (1)
Prev. Close 64.01
Today's Range 63.53 - 64.52
52wk Range 61.73 - 76.56
Shares Outstanding N/A
Dividend Yield 1.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets

Performance

YTD
-8.28%
-8.28%
1 Month
-0.72%
-0.72%
3 Month
-5.09%
-5.09%
6 Month
-13.26%
-13.26%
1 Year
-7.25%
-7.25%

More News

Read More
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Via Benzinga
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
Via Benzinga
AstraZeneca advances scientific leadership in hematology at ASH 2023
From AstraZeneca
Via Business Wire
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
Via Benzinga
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Via Talk Markets
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Via The Motley Fool
3 No-Brainer Stocks to Buy With $1,000 Right Now
Via The Motley Fool
5 Growth Stocks to Buy for 2024
Via InvestorPlace
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
From AstraZeneca
Via Business Wire
3 stocks that crushed earnings estimates and still tanked
Via MarketBeat
Exposures COVID-19
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
Via Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
Via The Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
Via Benzinga
Exposures Product Safety
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Via Benzinga
Exposures Product Safety
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
Via InvestorPlace
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Via Talk Markets
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
Via InvestorPlace
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.